Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010

Issa, Djamila E.; Schans, S.A.M. van de; Chamuleau, Martine E.D.; Karim‐Kos, Henrike E.; Wondergem, Mariëlle J.; Huijgens, Peter C.; Coebergh, Jan Willem; Zweegman, Sonja; Visser, Otto

doi:10.3324/haematol.2014.107300

Cited by 39 publications

(34 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is exceptional since these cancers are the main focus of previous studies showing an association of pregnancy-related events with cancer and the morbidity among Jewish populations as high [13]. However, this may be explained by the relatively short follow-up in this report with a later peak age of incidence of these cancers [24] and the inclusion of the non-Jewish population in the study, which have a lower cancer morbidity for breast and ovary [13]. In contrast, the peak incidence of hematologic and lymphatic malignancies occurs within the limits of the reproductive age.…”

Section: Discussioncontrasting

confidence: 77%

Delivery of a very low birth weight infant and increased maternal risk of cancer and death: a population study with 16 years of follow-up

Grisaru‐Granovsky

Gordon

Haklai

et al. 2015

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 77%

Delivery of a very low birth weight infant and increased maternal risk of cancer and death: a population study with 16 years of follow-up

Grisaru‐Granovsky

Gordon

Haklai

et al. 2015

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Due to advances in the treatment of lymphoma and chronic lymphocytic leukemia (CLL), a rising incidence, and aging of the population, the number of patients who are living with a history of lymphoma or CLL continues to grow. [1][2][3][4][5][6] It is expected that in 2020 there will be approximately 40,000 patients in the Netherlands who either are cured of their lymphoma or are living with it as a chronic disease, 7 an increase of approximately 65% compared with 2010.…”

Section: Introductionmentioning

confidence: 99%

More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: Results from the population‐based PROFILES registry

Arts

Oerlemans

Tick

et al. 2018

Cancer

View full text Add to dashboard Cite

BACKGROUNDFollow‐up care for a growing population of survivors of lymphoma and chronic lymphocytic leukemia (CLL) together with the adverse effects these survivors may experience as a result of their cancer and treatment have led to more pressure being placed on health care services. The objectives of the current study were to: 1) compare the use of medical care services by survivors with that of a normative population; 2) evaluate the use of medical and psychosocial care services among distressed and nondistressed survivors; and 3) identify associated sociodemographic and clinical factors.METHODSSurvivors of lymphoma and CLL diagnosed between 1999 and 2012 were selected via the population‐based Netherlands Cancer Registry and completed the Hospital Anxiety and Depression Scale questionnaire and questions regarding health care. Outcomes were compared with an age‐matched and sex‐matched normative population.RESULTSA total of 1444 survivors responded (69%). Survivors of lymphoma and CLL contacted their general practitioner (3.8 vs 2.3; P<.001) and medical specialist (5.7 vs 1.6; P<.001) more often within the last year compared with a normative population. In addition, psychologically distressed survivors had even more medical contacts and received psychosocial care more often compared with nondistressed survivors. In addition to psychological distress, comorbidity, female sex, and older age were found to be associated with a greater use of medical services, whereas younger age was associated with receiving psychosocial care.CONCLUSIONSSurvivors of lymphoma and CLL, especially those who are psychologically distressed, report an increased use of health care services compared with a normative population. Further studies are needed to explore whether the use of widely applicable psychosocial interventions could reduce the frequency of medical contacts. Cancer 2018;124:3016‐24. © 2018 Netherlands Comprehensive Cancer Organisation. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

show abstract

“…30,32 Thus, 3-year OS revealed by our routine data might be as high or even higher, since the age of our cohort with 68 years in median and 65 years in mean is similar to the median patients' age of 67-68 years reported from the aforementioned retrospective studies 30,32 and the LYFO and SLR registries 34 and also corresponds to the mean age of 66 years reported from the Netherlands Cancer Registry (NCR). 31 Patients with DLBCL from RCTs on R-CHOP treatment, however, usually had a lower median age of 52-64 years. 14,17,18 Similar to other registries like the NCR 31…”

Section: Best Response First-line Progression-free Survival and Ovmentioning

confidence: 99%

“…31 Patients with DLBCL from RCTs on R-CHOP treatment, however, usually had a lower median age of 52-64 years. 14,17,18 Similar to other registries like the NCR 31…”

Section: Best Response First-line Progression-free Survival and Ovmentioning

confidence: 99%

Similar effectiveness of R‐CHOP‐14 and ‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms

Knauf

Abenhardt²,

Mohm

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. AbstractObjectives: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B-cell lymphomas (DLBCL). Dose-dense two-weekly 'R-CHOP-14' was not superior over three-weekly 'R-CHOP-21' in randomised clinical trials (RCTs). We present realworld data on effectiveness of R-CHOP-14 and R-CHOP-21 in patients with DLBCL treated in German routine practice. Methods: We identified 582 patients with DLBCL treated with R-CHOP-14 or R-CHOP-21 in 92 sites from the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms. Patients' schedules were classified by (a) length of the initial first cycle and (b) length of cycles 1-4.Results: About 55% of patients received R-CHOP-21, 45% R-CHOP-14, in median 6 cycles. 51% and 55% of patients, respectively, were able to continue their initial R-CHOP-14 and R-CHOP-21 schedule. While most characteristics between the patient cohorts were similar, patients receiving R-CHOP-21 presented slightly more often with tumour stage I and lower IPI risk. 3-year overall survival of patients with R-CHOP-14 and R-CHOP-21 did not differ: 84% vs 84% (first cycle), 87% vs 89% (cycles 1-4). Conclusions:Patients with DLBCL in Germany are slightly more likely to receive R-CHOP-21 than R-CHOP-14. Both schedules are similarly effective in routine practice confirming the results from RCTs. K E Y W O R D Scohort studies, cyclophosphamide, doxorubicin, diffuse large B-cell lymphoma, outpatients, prednisone, prognosis, registries, rituximab, vincristine | 461 KNAUF et Al.

show abstract

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010

Cited by 39 publications

References 66 publications

Delivery of a very low birth weight infant and increased maternal risk of cancer and death: a population study with 16 years of follow-up

Delivery of a very low birth weight infant and increased maternal risk of cancer and death: a population study with 16 years of follow-up

More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: Results from the population‐based PROFILES registry

Similar effectiveness of R‐CHOP‐14 and ‐21 in diffuse large B‐cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms

Contact Info

Product

Resources

About